Beyond Air Inc. has entered into an agreement with Yissum Research Development Co. of the Hebrew University of Jerusalem to license the commercial rights for multiple neuronal nitric oxide synthase (nNOS) inhibitor candidates, currently being developed for the treatment of autism spectrum disorder (ASD) and other neurological conditions.